Table of Contents
ISRN Oncology
Volume 2014, Article ID 736163, 6 pages
http://dx.doi.org/10.1155/2014/736163
Research Article

Prior-Cancer Diagnosis in Men with Nonmetastatic Prostate Cancer and the Risk of Prostate-Cancer-Specific and All-Cause Mortality

1Harvard Radiation Oncology Program, Brigham and Woman’s Hospital and Department of Radiation Oncology, Dana-Farber Cancer Institute, 75 Francis Street, Boston, MA 02115, USA
2Department of Statistics, University of Connecticut, Storrs, CT 06269, USA
3Department of Radiation Oncology, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, MA 02115, USA

Received 18 November 2013; Accepted 16 December 2013; Published 30 January 2014

Academic Editors: T. I. Al-Saleem, G. Kovacs, and C. A. Perez

Copyright © 2014 Kristina Mirabeau-Beale et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. V. D'Amico, R. Whittington, S. Bruce Malkowicz et al., “Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer,” The Journal of the American Medical Association, vol. 280, no. 11, pp. 969–974, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. C. R. Pound, A. W. Partin, M. A. Eisenberger, D. W. Chan, J. D. Pearson, and P. C. Walsh, “Natural history of progression after PSA elevation following radical prostatectomy,” The Journal of the American Medical Association, vol. 281, no. 17, pp. 1591–1597, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. D. C. Miller, K. S. Hafez, A. Stewart, J. E. Montie, and J. T. Wei, “Prostate carcinoma presentation, diagnosis, and staging: an update from the National Cancer Data Base,” Cancer, vol. 98, no. 6, pp. 1169–1178, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Cassetti, F. Stracci, L. Minelli, M. Scheibel, I. E. Sapia, and F. La Rosa, “Metachronous malignancies in men with previous prostate cancer in Umbria, Italy, 1994–2003,” Tumori, vol. 94, no. 1, pp. 7–10, 2008. View at Google Scholar · View at Scopus
  5. M. E. Charlson, P. Pompei, K. A. Ales, and C. R. MacKenzie, “A new method of classifying prognostic comorbidity in longitudinal studies: development and validation,” Journal of Chronic Diseases, vol. 40, no. 5, pp. 373–383, 1987. View at Google Scholar · View at Scopus
  6. S. J. Freedland, W. J. Aronson, C. J. Kane et al., “Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the shared equal access regional cancer hospital database study group,” Journal of Clinical Oncology, vol. 22, no. 3, pp. 446–453, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. S. J. Freedland, L. Sun, C. J. Kane et al., “Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the shared equal access regional cancer hospital and Duke prostate center databases,” BJU International, vol. 102, no. 8, pp. 969–974, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Ho, L. Gerber, W. J. Aronson et al., “Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database,” European Urology, vol. 62, no. 5, pp. 910–916, 2012. View at Google Scholar
  9. J. F. Piccirillo, R. M. Tierney, I. Costas, L. Grove, and E. L. Spitznagel Jr., “Prognostic importance of comorbidity in a hospital-based cancer registry,” The Journal of the American Medical Association, vol. 291, no. 20, pp. 2441–2447, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Van Hemelrijck, L. Drevin, L. Holmberg, H. Garmo, J. Adolfsson, and P. Stattin, “Primary cancers before and after prostate cancer diagnosis,” Cancer, vol. 118, no. 24, pp. 6207–6216, 2012. View at Google Scholar
  11. E. Surveillance and End Results (SEER) Program, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, SEER*Stat Database: Incidence—SEER 17 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2010 Sub (1973–2008 varying)—Linked To County Attributes—Total U.S., 1969–2009 Counties, 2010, http://www.seer.cancer.gov/.
  12. J. P. Fine and R. J. Gray, “A proportional hazards model for the sub distribution of a competing risk,” Journal of the American Statistical Association, vol. 94, no. 446, pp. 496–509, 1999. View at Google Scholar · View at Scopus
  13. M. Hollander and D. A. Wolfe's, Nonparametric Statistical Methods, John Wiley & Sons, New York, NY, USA, 2nd edition, 1999.
  14. A. Agresti, Categorical Data Analysis, John Wiley & Sons, New York, NY, USA, 2nd edition, 2002.
  15. J. P. Klein and M. L. Moeschberger, Survival Analysis, Springer, New York, NY, USA, 2nd edition, 2003.
  16. J. J. Gaynor, E. J. Feuer, C. C. Tan et al., “On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data,” Journal of the American Statistical Association, vol. 88, pp. 400–409, 1993. View at Google Scholar
  17. E. L. Kaplan and P. Meier, “Nonparametric estimation from incomplete observations,” Journal of the American Statistical Association, vol. 53, pp. 447–457, 1958. View at Google Scholar
  18. L. A. Cupples, D. R. Gagnon, R. Ramaswamy, and R. B. D'Agostino, “Age-adjusted survival curves with application in the Framingham Study,” Statistics in Medicine, vol. 14, no. 16, pp. 1731–1744, 1995. View at Google Scholar · View at Scopus
  19. D. C. Miller, S. B. Gruber, B. K. Hollenbeck, J. E. Montie, and J. T. Wei, “Incidence of initial local therapy among men with lower-risk prostate cancer in the United States,” Journal of the National Cancer Institute, vol. 98, no. 16, pp. 1134–1141, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. J. L. Mohler, A. J. Armstrong, R. R. Bahnson et al., “Prostate cancer, version 3.2012: featured updates to the NCCN guidelines,” Journal of the National Comprehensive Cancer Network, vol. 10, no. 9, pp. 1081–1087, 2012. View at Google Scholar
  21. A. A. Aizer, J. J. Paly, A. L. Zietman et al., “Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer,” Journal of Clinical Oncology, vol. 30, no. 25, pp. 3071–3076, 2012. View at Google Scholar
  22. D. T. Miyamoto, R. J. Lee, S. L. Stott et al., “Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer,” Cancer Discovery, vol. 2, no. 11, pp. 995–1003, 2012. View at Google Scholar
  23. M. L. Liong, C. R. Lim, H. Yang et al., “Blood-based biomarkers of aggressive prostate cancer,” PLoS One, vol. 7, no. 9, Article ID e45802, 2012. View at Google Scholar
  24. D. Olmos, D. Brewer, J. Clark et al., “Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study,” The Lancet Oncology, vol. 13, no. 11, pp. 1114–1124, 2012. View at Google Scholar
  25. A. L. Russo, M. H. Chen, A. A. Aizer, J. A. Hattangadi, and A. V. D'Amico, “Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM),” BJU International, vol. 110, no. 7, pp. 973–979, 2012. View at Google Scholar